We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare & Medicaid Services (CMS) would like to develop a drug price index that could be used to compare the Medicare discount drug cards offered by various providers and the effects of the card program on drug prices over time, but the hitch lies in deciding which drugs to include in the index, CMS Administrator Mark McClellan told members of an agency advisory committee last week.
Entities hired by drugmakers to perform reviews required by corporate integrity agreements (CIAs) should meet the same standard for independence from the client drugmakers that the General Accounting Office has established for auditors of government contractors, the HHS Office of Inspector General (OIG) has announced.
The Centers for Medicare & Medicaid Services (CMS) would like to develop a drug price index that could be used to compare the Medicare discount drug cards offered by various providers and the effects of the card program on drug prices over time, but the hitch lies in deciding which drugs to include in the index, CMS Administrator Mark McClellan told members of an agency advisory committee yesterday.
A blue-ribbon panel established by NIH Director Elias Zerhouni has recommended that the National Institutes of Health's senior management employees and professional staff who manage grants not take consulting or speaking fees from drugmakers.
Entities hired by drugmakers to perform reviews required by corporate integrity agreements (CIAs) should meet the same standard for independence from the client drugmakers that the General Accounting Office has established for auditors of government contractors, the HHS Office of Inspector General (OIG) has announced.
Manufacturers of certain kidney disease drugs could soon face a marketing challenge and revenue pressures if the Centers for Medicare & Medicaid Services (CMS) responds to a price report from the HHS Office of Inspector General (OIG) by adjusting Medicare reimbursements for those drugs.
Two days after HHS Secretary Tommy Thompson said he believed Congress would pass legislation this session authorizing the importation of drugs from other countries, the head of a national retail pharmacy chain became the first industry leader to publicly endorse the concept.
For the first time ever, HHS Secretary Tommy Thompson last week approved plans allowing five states to pool their purchasing power to obtain deeper discounts from drugmakers on prescription drugs bought under the Medicaid program.
If states take the advice of the HHS Office of Inspector General (OIG) and start billing manufacturers for rebates on physician-administered drugs, drugmakers could have to fork over another $37 million a year or more in Medicaid drug rebates.
HHS is creating a new task force to assist in determining ways to help speed the development of new medical technologies and drug compounds, Secretary Tommy Thompson said in a speech last week.